# Claritev share price today (Claritev Corporation, CTEV)

> Claritev Corporation's balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. CTEV · Healthcare · Health Information Services · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/ctev

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $21.00 (−67.7% in a year)
- Revenue (Jun 2026): $257 M (+6.6% on a year ago)
- Profit (Jun 2026): −$59.2 M
- Operating margin: 12.8% (+1.9 points on a year ago)
- ROE: 170%, FY25
- ROIC: 2.0%, against a 7.0% cost of capital: −5.0 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Claritev share price today? Claritev Corporation's share price was $21.00 at the close on 3 November 2026. That is 17.9% below its average price over the last 200 trading days. In the last 52 weeks it traded between $13 and $69, and at that close it sat 13% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running. Over the last 1 year the share price moved −55% while the S&P 500 moved +21%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Claritev pay? Claritev Corporation pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Claritev on? Claritev is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Claritev profitable? Claritev Corporation posted a net loss of $59.2 M in the Jun 2026 quarter. The full FY25 year was a loss of $284 M. That loss is 23.0% of the quarter's revenue. The same quarter a year earlier lost $62.6 M. 12 of the last 12 reported quarters were loss-making. ## How much revenue does Claritev make, and is it growing? Claritev Corporation reported $257 M of revenue in the Jun 2026 quarter, +6.6% on the same quarter a year earlier. That is the 5th quarter in a row with growth on the year before. Over 4 years it has grown −3.6% a year on average. The last full year, FY25, came in at $965 M. The last four reported quarters add to $995 M. FY25 revenue was $965 M, +3.7% on the year before. Recent pace: the last four quarters grew +6.3% on average, against −3.6% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +6.3%, against +2.1% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Claritev keep? Claritev Corporation's operating margin was 12.8% in the Jun 2026 quarter, 1.9 percentage points higher than the same quarter a year ago. Across 5 years it has been between 9.3% and 35.4%. The latest quarter is within that range. Why the margin moved: operating margin changed +1.9 percentage points on the year while gross margin changed −1.1 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Claritev's profit turning into cash? Claritev Corporation's cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $117 M of operating cash against −$284 M of profit. After $130 M of spending on assets, free cash was −$12.3 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Claritev's cash go? Claritev Corporation does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $357 M on assets over the last 3 years. Averaged over those years that is 12.3% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $357 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Claritev's P/E ratio, and how does it compare with its own history? Claritev Corporation has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Claritev Corporation at 0.4× its FY25 revenue of $965 M. The P/E comes back here once profit turns positive. ## Is the Claritev business getting better or worse? Claritev Corporation's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Claritev earn on its capital? Claritev Corporation earned a ROE of 170% in FY25. That is up from a low of −1,959% in FY24. Its return on capital used (ROIC) is 5.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −29.4% net margin and 0.20× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −29.4% net margin × 0.20× asset turnover × −29.24× leverage (assets divided by equity) ≈ 171.9% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 2.0% − 7.0% = −5.0 percentage points. The 7.0% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Claritev have too much debt? Claritev Corporation's net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from 2.10 in FY21 to −27.65 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Claritev shareholding pattern? 13.4% of Claritev Corporation's tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 5.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Claritev from balance-sheet trouble? For Claritev Corporation, the Z-score is −0.40. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −0.40 is inside the danger zone, so the balance sheet is a real risk. ## How does Claritev rank in its industry? 37.4 out of 100, rank 22 of 29 in Health Information Services, with 64% of the evidence available. Claritev Corporation scores 37.4 out of 100 against the 29 companies it is compared with in Health Information Services, ranking 22. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 16.1 + 9.7 + 11 + 0.6 = 37.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Claritev compared with? Claritev ranks 22 of 29 Health Information Services companies on the 4-Factor Sector Score, with 37.4 out of 100. 1. [Hinge Health, Inc.](https://www.sectoralpha.in/us/stocks/hnge) HNGE · leader · Most evidence points up · 64% evidence 72.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.5/35 · Revenue 49.7% · Profit n/a · Operating margin change 436.5 points · 62% evidence Capital efficiency 19.0/25 · ROCE 27.1% · Operating margin 19% · 76% evidence Valuation 9.3/20 · P/E 59.8× · PEG n/a · 15% evidence Relative strength 17.7/20 · Lead over its industry 42% · Lead over S&P 500 75.7% · 1 year 162.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.5 + 19 + 9.3 + 17.7 = 72.5 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Veeva Systems Inc.](https://www.sectoralpha.in/us/stocks/veev) VEEV · breaking out · Most evidence points up · 85% evidence 69.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.9/35 · Revenue 16.5% · Profit 25.2% · Operating margin change 0.9 points · 95% evidence Capital efficiency 18.8/25 · ROCE 13.6% · Operating margin 29.6% · 76% evidence Valuation 13.0/20 · P/E 32.6× · PEG 1.3 · 65% evidence Relative strength 16.9/20 · Lead over its industry 6.4% · Lead over S&P 500 33.9% · 1 year 2.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.9 + 18.8 + 13 + 16.9 = 69.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [HeartFlow, Inc.](https://www.sectoralpha.in/us/stocks/htfl) HTFL · leader · Evidence leans up · 61% evidence 57.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 43.2% · Profit n/a · Operating margin change 3.7 points · 62% evidence Capital efficiency 4.5/25 · ROCE -24.2% · Operating margin -27.9% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 19.2/20 · Lead over its industry 23.6% · Lead over S&P 500 54.5% · 1 year 67.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24 + 4.5 + 10 + 19.2 = 57.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Waystar Holding Corp.](https://www.sectoralpha.in/us/stocks/way) WAY · breaking out · Evidence leans up · 81% evidence 55.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.7/35 · Revenue 19.4% · Profit 58.8% · Operating margin change 0.4 points · 83% evidence Capital efficiency 12.2/25 · ROCE 5.2% · Operating margin 24.4% · 76% evidence Valuation 15.6/20 · P/E 29.2× · PEG 0.64 · 65% evidence Relative strength 8.0/20 · Lead over its industry -20.2% · Lead over S&P 500 2% · 1 year -23.6% · 100% evidence · 11 of 12 weeks ahead Exact sum: 19.7 + 12.2 + 15.6 + 8 = 55.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Schrödinger, Inc.](https://www.sectoralpha.in/us/stocks/sdgr) SDGR · leader · Evidence leans up · 64% evidence 55.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 8.8% · Profit n/a · Operating margin change 26 points · 62% evidence Capital efficiency 4.6/25 · ROCE -32.9% · Operating margin -70.6% · 76% evidence Valuation 11.2/20 · P/E -22.3× · PEG n/a · 15% evidence Relative strength 18.5/20 · Lead over its industry 22.6% · Lead over S&P 500 53% · 1 year 52.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21 + 4.6 + 11.2 + 18.5 = 55.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [HealthEquity, Inc.](https://www.sectoralpha.in/us/stocks/hqy) HQY · quiet · Evidence leans up · 85% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 7.4% · Profit 62.3% · Operating margin change 0.5 points · 95% evidence Capital efficiency 16.1/25 · ROCE 11.4% · Operating margin 28.4% · 76% evidence Valuation 11.6/20 · P/E 35.6× · PEG 1.53 · 65% evidence Relative strength 6.1/20 · Lead over its industry -15.9% · Lead over S&P 500 7.3% · 1 year 8.9% · 100% evidence · 5 of 12 weeks ahead Exact sum: 21.4 + 16.1 + 11.6 + 6.1 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [BrightSpring Health Services, Inc.](https://www.sectoralpha.in/us/stocks/btsg) BTSG · turning · Too little evidence to rank firmly · 56% evidence 53.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.0/35 · Revenue n/a · Profit n/a · Operating margin change 1.6 points · 39% evidence Capital efficiency 12.6/25 · ROCE 10.1% · Operating margin 3.4% · 76% evidence Valuation 10.0/20 · P/E 39.7× · PEG n/a · 15% evidence Relative strength 11.3/20 · Lead over its industry 2.2% · Lead over S&P 500 29.7% · 1 year 110.7% · 100% evidence · 2 of 12 weeks ahead Exact sum: 20 + 12.6 + 10 + 11.3 = 53.9 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 8. [Doximity, Inc.](https://www.sectoralpha.in/us/stocks/docs) DOCS · breaking out · Evidence leans up · 81% evidence 53.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.5/35 · Revenue 11.2% · Profit -28.6% · Operating margin change -16.3 points · 83% evidence Capital efficiency 20.9/25 · ROCE 21.6% · Operating margin 21.5% · 76% evidence Valuation 10.8/20 · P/E 22.7× · PEG 1.74 · 65% evidence Relative strength 9.8/20 · Lead over its industry -17.6% · Lead over S&P 500 5.1% · 1 year -40% · 100% evidence · 12 of 12 weeks ahead Exact sum: 11.5 + 20.9 + 10.8 + 9.8 = 53 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Tempus AI, Inc.](https://www.sectoralpha.in/us/stocks/tem) TEM · breaking out · Evidence leans up · 64% evidence 51.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.1/35 · Revenue 50.2% · Profit n/a · Operating margin change -0.6 points · 62% evidence Capital efficiency 5.6/25 · ROCE -14.3% · Operating margin -19.6% · 76% evidence Valuation 11.4/20 · P/E -40.9× · PEG n/a · 15% evidence Relative strength 14.4/20 · Lead over its industry -1.4% · Lead over S&P 500 25% · 1 year 8.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.1 + 5.6 + 11.4 + 14.4 = 51.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Phreesia, Inc.](https://www.sectoralpha.in/us/stocks/phr) PHR · turning · Evidence leans down · 67% evidence 47.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 12.7% · Profit n/a · Operating margin change 7.2 points · 71% evidence Capital efficiency 9.5/25 · ROCE 4.3% · Operating margin 5.9% · 76% evidence Valuation 9.0/20 · P/E 63.5× · PEG n/a · 15% evidence Relative strength 5.7/20 · Lead over its industry -26.7% · Lead over S&P 500 -6.1% · 1 year -44.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 23.7 + 9.5 + 9 + 5.7 = 47.9 · What this means: Earnings are strong; relative strength in its sector is -26.7% and the one-year return is -44.5%. 11. [NRC Health](https://www.sectoralpha.in/us/stocks/nrc) NRC · turning · Evidence leans down · 64% evidence 47.7 out of 100 Growth Capital Valuation Relative
12. [Certara, Inc.](https://www.sectoralpha.in/us/stocks/cert) CERT · leader · Evidence leans down · 64% evidence 46.4 out of 100 Growth Capital Valuation Relative
13. [HealthStream, Inc.](https://www.sectoralpha.in/us/stocks/hstm) HSTM · leader · Evidence leans down · 81% evidence 46.2 out of 100 Growth Capital Valuation Relative
14. [Spok Holdings, Inc.](https://www.sectoralpha.in/us/stocks/spok) SPOK · turning · Evidence leans down · 81% evidence 46.1 out of 100 Growth Capital Valuation Relative
15. [American Well Corporation](https://www.sectoralpha.in/us/stocks/amwl) AMWL · losing its lead · Evidence leans down · 61% evidence 45.2 out of 100 Growth Capital Valuation Relative
16. [10x Genomics, Inc.](https://www.sectoralpha.in/us/stocks/txg) TXG · leader · Evidence leans down · 64% evidence 45.1 out of 100 Growth Capital Valuation Relative
17. [Omada Health, Inc.](https://www.sectoralpha.in/us/stocks/omda) OMDA · quiet · Evidence leans down · 64% evidence 44.9 out of 100 Growth Capital Valuation Relative
18. [Privia Health Group, Inc.](https://www.sectoralpha.in/us/stocks/prva) PRVA · basing · Evidence leans down · 81% evidence 43.0 out of 100 Growth Capital Valuation Relative
19. [Omnicell, Inc.](https://www.sectoralpha.in/us/stocks/omcl) OMCL · basing · Evidence leans down · 71% evidence 42.7 out of 100 Growth Capital Valuation Relative
20. [Carlsmed, Inc.](https://www.sectoralpha.in/us/stocks/carl) CARL · breaking out · Evidence leans down · 61% evidence 41.2 out of 100 Growth Capital Valuation Relative
21. [Teladoc Health, Inc.](https://www.sectoralpha.in/us/stocks/tdoc) TDOC · turning · Evidence leans down · 61% evidence 41.2 out of 100 Growth Capital Valuation Relative
22. Claritev Corporation this page CTEV · quiet · Evidence leans down · 64% evidence 37.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.1/35 · Revenue 6.4% · Profit n/a · Operating margin change 1.9 points · 62% evidence Capital efficiency 9.7/25 · ROCE 2.2% · Operating margin 12.8% · 76% evidence Valuation 11.0/20 · P/E -1.1× · PEG n/a · 15% evidence Relative strength 0.6/20 · Lead over its industry -43.7% · Lead over S&P 500 -28.8% · 1 year -69.7% · 100% evidence · 5 of 12 weeks ahead Exact sum: 16.1 + 9.7 + 11 + 0.6 = 37.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 23. [SOPHiA GENETICS SA](https://www.sectoralpha.in/us/stocks/soph) SOPH · losing its lead · Evidence leans down · 61% evidence 37.1 out of 100 Growth Capital Valuation Relative
24. [Evolent Health, Inc.](https://www.sectoralpha.in/us/stocks/evh) EVH · turning · Evidence leans down · 64% evidence 36.9 out of 100 Growth Capital Valuation Relative
25. [GoodRx Holdings, Inc.](https://www.sectoralpha.in/us/stocks/gdrx) GDRX · quiet · Most evidence points down · 81% evidence 33.9 out of 100 Growth Capital Valuation Relative
26. [Simulations Plus, Inc.](https://www.sectoralpha.in/us/stocks/slp) SLP · Too little evidence to rank firmly · 44% evidence 56.3 out of 100 Growth Capital Valuation Relative
27. [Talkspace, Inc.](https://www.sectoralpha.in/us/stocks/talk) TALK · Too little evidence to rank firmly · 44% evidence 48.4 out of 100 Growth Capital Valuation Relative
28. [Weave Communications, Inc.](https://www.sectoralpha.in/us/stocks/weav) WEAV · Too little evidence to rank firmly · 41% evidence 47.7 out of 100 Growth Capital Valuation Relative
29. [TruBridge, Inc.](https://www.sectoralpha.in/us/stocks/tbrg) TBRG · Too little evidence to rank firmly · 31% evidence 42.2 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Health Information Services](https://www.sectoralpha.in/us/sectors/health-information-services), all 29 compared on one page. ## Which companies are close to Claritev in size? Claritev is the 27th largest of 30 Health Information Services companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Carlsmed, Inc., TruBridge, Inc. and Simulations Plus, Inc. Just below it: Spok Holdings, Inc., American Well Corporation and So-Young International Inc. ### Health Information Services companies close in size

1. [Carlsmed, Inc.](https://www.sectoralpha.in/us/stocks/carl) $393 million
2. [TruBridge, Inc.](https://www.sectoralpha.in/us/stocks/tbrg) $388 million
3. [Simulations Plus, Inc.](https://www.sectoralpha.in/us/stocks/slp) $374 million
4. Claritev Corporation $356 million
5. [Spok Holdings, Inc.](https://www.sectoralpha.in/us/stocks/spok) $251 million
6. [American Well Corporation](https://www.sectoralpha.in/us/stocks/amwl) $217 million
7. [So-Young International Inc.](https://www.sectoralpha.in/us/stocks/sy) $200 million

[All 30 Health Information Services companies, largest first](https://www.sectoralpha.in/us/sectors/health-information-services#all-companies)

### Companies close in size in other industries

1. [Allogene Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/allo) $408 million · Biotechnology
2. [Genesco Inc.](https://www.sectoralpha.in/us/stocks/gco) $407 million · Apparel Retail
3. Claritev Corporation $407 million
4. [Dingdong (Cayman) Limited](https://www.sectoralpha.in/us/stocks/ddl) $406 million · Grocery Stores
5. [Telos Corporation](https://www.sectoralpha.in/us/stocks/tls) $405 million · Software - Infrastructure

## What else do people ask about Claritev? ### What were Claritev's latest quarterly results? Claritev Corporation reported revenue of $257 M and a net loss of $59.2 M for the Jun 2026 quarter. Earnings per share were −$3.49. The operating margin was 12.8%, 1.9 percentage points higher than a year earlier (as of 3 November 2026). ### What is Claritev's market cap? Claritev Corporation's market capitalisation is $356 M at a stock price of $21.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Claritev performing? Claritev Corporation's latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Claritev's stock price go up? This page does not forecast Claritev Corporation's stock price. What it shows instead: the stock price is $21.00. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Claritev in its business cycle? Claritev Corporation's FY25 operating margin was 9.3%, against a 5-year range of 9.3% to 35.4%: the low end of its own range, which is often where recoveries start. The latest quarter was 12.8%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Claritev story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Claritev a stock worth studying right now? What the numbers show: Claritev Corporation's balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. The main open question: whether the business can earn its way back to positive net worth before new shares or a restructuring get there first. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.